161 related articles for article (PubMed ID: 35543239)
1. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
Dinakar S; Gurubarath M; Dhananjayan K
J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
[TBL] [Abstract][Full Text] [Related]
2. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation.
Elangovan ND; Dhanabalan AK; Gunasekaran K; Kandimalla R; Sankarganesh D
J Biomol Struct Dyn; 2021 Nov; 39(18):7065-7079. PubMed ID: 32779973
[TBL] [Abstract][Full Text] [Related]
3. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
4. Screening of
Chandel S; Singh R; Gautam A; Ravichandiran V
J Biomol Struct Dyn; 2022; 40(23):12827-12840. PubMed ID: 34569452
[TBL] [Abstract][Full Text] [Related]
5. Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3β: A Putative Target to Combat Mortality in Patients with COVID-19.
Khamverdi Z; Mohamadi Z; Taherkhani A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):16-34. PubMed ID: 35253634
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
8. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-Based Screening, Molecular Docking, and Dynamic Simulation of Fungal Metabolites as Inhibitors of Multi-Targets in Neurodegenerative Disorders.
Iqbal D; Alsaweed M; Jamal QMS; Asad MR; Rizvi SMD; Rizvi MR; Albadrani HM; Hamed M; Jahan S; Alyenbaawi H
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002295
[TBL] [Abstract][Full Text] [Related]
10. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
11. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity.
Hu XL; Guo C; Hou JQ; Feng JH; Zhang XQ; Xiong F; Ye WC; Wang H
ACS Chem Neurosci; 2019 Feb; 10(2):996-1007. PubMed ID: 29944335
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays.
Balboni B; Tripathi SK; Veronesi M; Russo D; Penna I; Giabbai B; Bandiera T; Storici P; Girotto S; Cavalli A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409221
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking study of GSK-3β interaction with nomilin, kihadanin B, and related limonoids and triterpenes with a furyl-δ-lactone core.
Vergoten G; Bailly C
J Biochem Mol Toxicol; 2022 Sep; 36(9):e23130. PubMed ID: 35686814
[TBL] [Abstract][Full Text] [Related]
15. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues.
Han S; Zhou W; Zhuang C; Chen F
Bioorg Chem; 2022 Feb; 119():105537. PubMed ID: 34902644
[TBL] [Abstract][Full Text] [Related]
17. Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases.
Gianferrara T; Cescon E; Grieco I; Spalluto G; Federico S
Curr Med Chem; 2022; 29(27):4631-4697. PubMed ID: 35170406
[TBL] [Abstract][Full Text] [Related]
18. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
19. (Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3β inhibitor: Identification by virtual screening and its validation in enzyme- and cell-based assay.
Joshi P; Gupta M; Vishwakarma RA; Kumar A; Bharate SB
Chem Biol Drug Des; 2017 Jun; 89(6):964-971. PubMed ID: 27896926
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
